Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.…
Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Chemomab Therapeutics (NASDAQ: CMMB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 1.190 USD on 20 November 2026, down 55.6% over 52 weeks. Its 52-week range is 0.9201 USD to 2.941 USD: the price is 59.5% below the high and 29.3% above the low.
Its market capitalisation is 9.58M USD.
Chemomab Therapeutics reports return on equity of -72.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 6.69M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.